WallStSmart

Teck Resources Ltd Class B (TECK)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teck Resources Ltd Class B generates 285% more annual revenue ($12.41B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 14.9%. WST appears more attractively valued with a PEG of 2.89. TECK earns a higher WallStSmart Score of 73/100 (B).

TECK

Strong Buy

73

out of 100

Grade: B

Growth: 7.3Profit: 6.0Value: 4.7Quality: 6.8
Piotroski: 7/9Altman Z: 1.93

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

TECKUndervalued (+9.1%)

Margin of Safety

+9.1%

Fair Value

$66.42

Current Price

$60.76

$5.66 discount

UndervaluedFair: $66.42Overvalued
WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$325.92

$139.97 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TECK4 strengths · Avg: 9.5/10
Operating MarginProfitability
39.8%10/10

Strong operational efficiency at 39.8%

Revenue GrowthGrowth
72.2%10/10

Revenue surging 72.2% year-over-year

EPS GrowthGrowth
128.8%10/10

Earnings expanding 128.8% YoY

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

TECK3 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.934/10

Grey zone — moderate risk

Return on EquityProfitability
5.9%3/10

ROE of 5.9% — below average capital efficiency

PEG RatioValuation
5.472/10

Expensive relative to growth rate

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : TECK

The strongest argument for TECK centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 72.2% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : TECK

The primary concerns for TECK are Altman Z-Score, Return on Equity, PEG Ratio.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

TECK carries more volatility with a beta of 1.57 — expect wider price swings.

TECK is growing revenue faster at 72.2% — sustainability is the question.

TECK generates stronger free cash flow (344M), providing more financial flexibility.

Monitor OTHER INDUSTRIAL METALS & MINING industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TECK scores higher overall (73/100 vs 67/100) and 72.2% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Teck Resources Ltd Class B

BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA

Teck Resources Limited is dedicated to exploring, acquiring, developing and producing natural resources in Asia, Europe and North America. The company is headquartered in Vancouver, Canada.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?